Hepatitis C News and Research RSS Feed - Hepatitis C News and Research

Hepatitis C is a blood-borne virus that infects the liver, where it causes significant inflammation, damage and disruption of normal liver function. According to estimates by the World Health Organization, around 3 to 4 million people worldwide are infected with hepatitis C every year.

The hepatitis C virus is usually transmitted through contact with the blood of an infected individual and, most commonly, people catch it through sharing contaminated needles when injecting illegal drugs.

Hepatitis C infection is categorized into an acute and a chronic stage. The acute phase describes the first 6 months of infection when there are not necessarily any symptoms. Around one quarter of people manage to clear the infection during this stage before disease progresses to the chronic stage.

People who go on to develop chronic hepatitis C may develop jaundice which turns the skin and whites of the eyes yellow. This is caused by the build-up of a yellow-colored substance in the blood called bilirubin that would usually be broken down by the liver if it was healthy. Chronic infection may eventually cause fibrosis and scarring (cirrhosis) of the liver, liver cancer or end stage liver failure.

Hepatitis C can be treated with antiviral medications that that are designed to disrupt the multiplication of virus particles inside the body and prevent liver damage.
Scientists use new technique to repair fibrotic liver cells within the organ

Scientists use new technique to repair fibrotic liver cells within the organ

Advances in stem cell research have made it possible to convert patients' skin cells into heart cells, kidney cells, liver cells and more in the lab dish, giving researchers hope that one day such cells could replace organ transplantation for patients with organ failure. [More]
First ECHO model helps improve screening and management of autism

First ECHO model helps improve screening and management of autism

Wait lists for a specialist to confirm an autism diagnosis can be agonizing and last months. As the prevalence of autism and autism spectrum disorders increase, so does the demand for a health care system that is fully equipped to respond to the complex needs associated with autism. [More]
Research sheds light on potential impact of HCV treatment in preventing virus transmission

Research sheds light on potential impact of HCV treatment in preventing virus transmission

An international team of researchers has shed light on the potential impact of new drugs for hepatitis C virus (HCV). [More]
Experimental hepatitis C drug slows down development of Zika in mice

Experimental hepatitis C drug slows down development of Zika in mice

Virologists from KU Leuven, Belgium, have shown that an experimental antiviral drug against hepatitis C slows down the development of Zika in mice. The research team was led by Professor Johan Neyts from the Laboratory of Virology and Chemotherapy. [More]
New national survey reveals that asthma patients most frequently use rescue inhaler

New national survey reveals that asthma patients most frequently use rescue inhaler

In a new national survey of asthma patients, Health Union, and its new online community Asthma.net, reveals that most were satisfied with the care they received; however, the most frequently used form of treatment, at 89%, is the rescue inhaler. [More]
New study sheds more light on level of alcohol consumption among people with hepatitis C

New study sheds more light on level of alcohol consumption among people with hepatitis C

Drinking alcohol can increase the risk of illness and death from the hepatitis C virus. A new national household study of U.S. adults published in the American Journal of Preventive Medicine shows that many people living with hepatitis C report either former or current excessive alcohol use. [More]
Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

The survival rate of patients with hepatitis C virus-related cirrhosis who respond well to antiviral therapies equals that of the general population, say investigators in the Journal of Hepatology. [More]
Study on Zika exposure among HIV-infected patients in Ghana

Study on Zika exposure among HIV-infected patients in Ghana

What many may not know is that the Zika virus is a distant cousin of hepatitis C, a blood borne-virus that attacks the liver and often co-infects HIV patients. [More]
WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

Japanese researchers have found that serum levels of glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein are a useful marker of not only the degree of liver fibrosis, but also progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. [More]
Serum marker may flag liver fibrosis in chronic HBV

Serum marker may flag liver fibrosis in chronic HBV

Serum levels of Wisteria floribunda agglutinin-positive Mac-2-binding protein may reflect the severity of liver fibrosis in patients with chronic hepatitis B virus infection, say researchers. [More]
New blood treatment technology could reduce malaria risk following blood transfusions

New blood treatment technology could reduce malaria risk following blood transfusions

Patients, especially children, who undergo blood transfusions in sub-Saharan Africa are at high risk of transfusion-transmitted malaria. A new trial, published in The Lancet today, suggests that treating donated blood with a new technology that combines UV radiation and vitamin B is safe and could minimise the risk of malaria infection following blood transfusions. [More]
Johns Hopkins study suggests updated universal screening for hepatitis C virus

Johns Hopkins study suggests updated universal screening for hepatitis C virus

A review of blood samples for nearly 5,000 patients seen at The Johns Hopkins Hospital Emergency Department suggests that federal guidelines for hepatitis C virus (HCV) screening may be missing up to a quarter of all cases and argues for updated universal screening. [More]
AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie, a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with ribavirin (RBV) in the primary intent-to-treat analysis. [More]
VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

AbbVie, a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12). [More]
Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs). [More]
Hepatitis C treatment can be provided safely, effectively within community-based setting

Hepatitis C treatment can be provided safely, effectively within community-based setting

A new study, presented today, demonstrates treatment for Hepatitis C can be provided safely and effectively within a community-based and non-specialist setting. This illustrates the potential for alternative providers to ease pressure on currently overburdened specialists. The study, sponsored by the National Institutes of Health, was presented at The International Liver Congress 2016 in Barcelona, Spain. [More]
HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a 'high rate' of re-developing their illness. [More]
Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Two separate studies presented today at The International Liver Congress 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with HIV and Hepatitis C virus (HCV). [More]
Prime boost approach can increase possibility of combined HCV and HIV vaccination

Prime boost approach can increase possibility of combined HCV and HIV vaccination

A combined vaccination against Hepatitis C virus (HCV) and HIV moved a step closer, with the results of a study presented at The International Liver Congress 2016 in Barcelona, Spain today. [More]
Inactivation of protein-coding gene promotes liver tissue regeneration in mammals

Inactivation of protein-coding gene promotes liver tissue regeneration in mammals

Scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) report that inactivating a certain protein-coding gene promotes liver tissue regeneration in mammals. [More]
Advertisement